Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients

Phase 2

Completed

Conditions: HCMV

Interventions: Biological: CSJ148
Drug: Placebo

First Posted Date: 2014-10-20

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 86

Registration Number: NCT02268526

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)

Phase 1

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: branaplam

First Posted Date: 2014-10-20

Last Posted Date: 2025-04-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT02268552

Locations: 🇷🇺
Novartis Investigative Site, Volgograd, Russian Federation

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Phase 3

Completed

Conditions: Chronic Scalp Psoriasis

Interventions: Biological: Secukinumab 300 mg
Biological: Placebo

First Posted Date: 2014-10-17

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 102

Registration Number: NCT02267135

Locations: 🇺🇸
Novartis Investigative Site, West Jordan, Utah, United States

Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Wait and Extend regime arm
Drug: Labeled regime arm

First Posted Date: 2014-10-13

Last Posted Date: 2019-06-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 87

Registration Number: NCT02262260

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey

A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients

Phase 3

Completed

Conditions: Diabetic Macular Edema
Visual Impairment

Interventions: Drug: Ranibizumab (RFB002)
Procedure: Laser
Procedure: Sham laser
Drug: Sham injection

First Posted Date: 2014-10-08

Last Posted Date: 2019-02-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 384

Registration Number: NCT02259088

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 4

Withdrawn

Conditions: Visual Impairment Due to Diabetic Macular Edema

Interventions: Drug: Ranibizumab
Drug: Aflibercept

First Posted Date: 2014-10-07

Last Posted Date: 2016-10-27

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02258009

Locations: 🇩🇪
Novartis Investigative Site, Chemnitz, Germany

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Phase 4

Completed

Conditions: Wet Age-Related Macular Degeneration

Interventions: Drug: Ranibizumab 0.5 mg
Drug: Aflibercept 2 mg

First Posted Date: 2014-10-06

Last Posted Date: 2019-05-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT02257632

Locations: 🇩🇪
Novartis Investigative Site, Regensburg, Germany

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Nilotinib
Drug: Ruxolitinib

First Posted Date: 2014-10-01

Last Posted Date: 2019-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT02253277

Locations: 🇩🇪
Novartis Investigative Site, Leipzig, Germany

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase 2

Completed

Conditions: Sporadic Inclusion Body Myositis (sIBM)

Interventions: Drug: BYM338 (Bimagrumab)

First Posted Date: 2014-09-26

Last Posted Date: 2020-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT02250443

Locations: 🇺🇸
Novartis Investigative Site, Boston, Massachusetts, United States

Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa

Phase 4

Terminated

Conditions: Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis

Interventions: Drug: TIS or TIP

First Posted Date: 2014-09-25

Last Posted Date: 2018-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT02248922

Locations: 🇩🇪
Novartis Investigative Site, Jena, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy